Surmodics Announces 2017 Annual Shareholders Meeting

February 9, 2017 at 8:00 AM EST

Virtual Meeting on February 14 at 4:00 p.m. (CT)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Feb. 9, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that its virtual Annual Meeting of Shareholders will be held on Tuesday, February 14, at 4:00 p.m. CT (5:00 p.m. ET).

Gary Maharaj, chief executive officer, and Sue Knight, chair of the board, will provide a brief update on business and key strategic initiatives underway at the Company.

To attend the meeting, go to five minutes prior to the start of the meeting to log in. In addition, the Annual Meeting audio presentation will be archived on the Company’s website following the meeting.

About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the Company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to meet the most demanding requirements. With this focus on offering total product solutions, Surmodics’ mission remains to improve the detection and treatment of disease by using its technology to provide solutions to difficult medical device and diagnostic challenges. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the company, visit The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.

Source: Surmodics, Inc.

Surmodics, Inc.
Andy LaFrence, 952-500-7000